Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study

Abstract

<b><i>Introduction:</i></b> Omalizumab is a humanized anti-IgE monoclonal antibody, which is effective in the treatment in patients with chronic spontaneous urticaria (CSU) who are unresponsive to antihistamine therapy. There are few studies in the literature evaluating omalizumab treatment response in patients with symptomatic dermographism (SDerm). The aim of this study was to compare the response to omalizu­mab treatment in patients with CSU and SDerm. <b><i>Methods:</i></b> Patients treated with omalizumab for the diagnosis of CSU and SDerm were evaluated retrospectively. Treatment response to omalizumab was evaluated with the urticaria control test (UCT). Quality of life was evaluated with the dermatology quality of life questionnaire (DLQI). Baseline UCT and DLQI were compared with UCT and DLQI after omalizumab treatment. <b><i>Results:</i></b> Evaluation was made of a total of 116 patients (CSU: 92, SDerm: 24), comprising 36 (31%) males and 80 (69%) females with a mean age of 38.95 ± 13.64 years. The most common accompanying comorbid disease was allergic rhinitis (<i>n</i> = 40, 34.5%). There was no statistically significant difference between patients with CSU and SDerm in respect of response to omalizumab treatment (<i>p</i> = 0.890). After omalizumab treatment, the increase in UCT and decrease in DLQI was statistically significant in all patient groups (<i>p</i> &#x3c; 0.001; <i>p</i> &#x3c; 0.001, respectively), patients with CSU (<i>p</i> &#x3c; 0.001; <i>p</i> &#x3c; 0.001, respectively) and SDerm (<i>p</i> &#x3c; 0.001; <i>p</i> &#x3c; 0.001, respectively). There was no statistically significant difference between baseline (before omalizumab treatment) UCT (<i>p</i> = 0.804) and UCT after omalizumab treatment (<i>p</i> = 0.933) between patients with CSU and patients with SDerm. There was no statistically significant difference between baseline (before omalizumab treatment) DLQI (<i>p</i> = 0.356) and DLQI after omalizumab treatment (<i>p</i> = 0.145) between patients with CSU and patients with SDerm. <b><i>Conclusion:</i></b> Omalizumab treatment improved disease control and quality of life in patients with SDerm. The findings of this study should be supported by randomized placebo-controlled studies.